Esperion to Report Second Quarter 2021 Financial Results August 3, 2021
July 13 2021 - 8:00AM
Esperion (NASDAQ: ESPR), today announced it will report second
quarter 2021 financial results before the open of the U.S.
financial markets on Tuesday, August 3, 2021.
Following the release, company management will host a webcast
and conference call at 8:00 a.m. ET to discuss financial results
and business progress. The call can be accessed by dialing (877)
831-3840 (domestic) or (253) 237-1184 (international) five minutes
prior to the start of the call and providing the access code
4975714.
A live audio webcast can be accessed on the investor and media
section of the Esperion website at investor.esperion.com. Access to
the webcast replay will be available approximately two hours after
completion of the call and will be archived on the Company's
website for approximately 90 days.
ESPERION Therapeutics
ESPERION is The Lipid Management Company. Our goal is lipid
management for everybody, that’s why we work hard to make our
medicines easy to get, easy to take and easy to have. We discover,
develop and commercialize innovative medicines and combinations to
lower cholesterol, especially for patients whose needs aren’t being
met by the status quo. Our entrepreneurial team of industry leaders
is inclusive, passionate and resourceful. We are singularly focused
on managing cholesterol so you can improve your health easily.
ESPERION commercializes NEXLETOL® (bempedoic acid) and NEXLIZET®
(bempedoic acid and ezetimibe) Tablets and is the leader in the
development of convenient oral, once-daily non-statin
LDL-cholesterol lowering drugs for patients with high levels of bad
cholesterol. For more information, please visit www.esperion.com
and follow us on Twitter at www.twitter.com/EsperionInc.
Investor Contact:Kaitlyn
BroscoEsperioncorporateteam@esperion.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024